(Q37356496)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102670%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

review article

1 reference

title

Role of the cholinergic system in the pathology and treatment of schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102670%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

0 references

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102670%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Elizabeth Scarr

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102670%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102670%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102670%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102670%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102670%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

73-86

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102670%20AND%20SRC:MED&resulttype=core&format=json

Genetics of atherosclerosis

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Subtyping schizophrenia: implications for genetic research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Drug strategies and treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

The current status of the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Treatment of cognitive dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

The pipeline and future of drug development in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

The cholinergic 'pitfall': acetylcholine, a universal cell molecule in biological systems, including humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Identification and characterization of the high-affinity choline transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Acetylcholine in mind: a neurotransmitter correlate of consciousness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Neuronal nicotinic acetylcholine receptors: from the genetic analysis to neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Brain nicotinic acetylcholine receptors: native subtypes and their relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Identification of a family of muscarinic acetylcholine receptor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Muscarinic acetylcholine receptors as CNS drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

M1-M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Muscarinic receptors in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Midbrain acetylcholine and glutamate receptors modulate accumbal dopamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Modulation of synaptic plasticity by physiological activation of M1 muscarinic acetylcholine receptors in the mouse hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Muscarinic suppression in stratum radiatum of CA1 shows dependence on presynaptic M1 receptors and is not dependent on effects at GABA(B) receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Neuromodulators control the polarity of spike-timing-dependent synaptic plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Half a century of antipsychotics and still a central role for dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Association of anticholinergic load with impairment of complex attention and memory in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Low levels of alpha7-nicotinic acetylcholine receptor mRNA on peripheral blood lymphocytes in schizophrenia and its association with illness severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Regulation of alpha7-nicotinic receptor subunit and alpha7-like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

RGS4 mRNA expression in postmortem human cortex is associated with COMT Val158Met genotype and COMT enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Alpha7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Characterization of allelic variants at chromosome 15q14 in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Comparison of polymorphisms in the alpha7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Identification of molecular variants at the promoter region of the human alpha 7 neuronal nicotinic acetylcholine receptor subunit gene but lack of association with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Linkage of M5 muscarinic and alpha7-nicotinic receptor genes on 15q13 to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

The promoter -194 C polymorphism of the nicotinic alpha 7 receptor gene has a protective effect against the P50 sensory gating deficit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Nicotinic acetylcholine involvement in cognitive function in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Nicotine: from molecular mechanisms to behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Genetic interaction between alpha4 and beta2 subunits of high affinity nicotinic receptor: analysis in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Genetic association analysis of tagging SNPs in alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes (CHRNA4 and CHRNB2) with schizophrenia in the Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in schizophrenia families

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Tropisetron improves deficits in auditory P50 suppression in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Improved p50 auditory gating with ondansetron in medicated schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Initial phase 2 trial of a nicotinic agonist in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

The effect of galantamine added to clozapine on cognition of five patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Galantamine for the treatment of cognitive impairments in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Neurotransmitter Receptors in Frontal Cortex of Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

5-HT2A and muscarinic receptors in schizophrenia: a postmortem study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

P50 sensory gating deficit is a common marker of vulnerability to bipolar disorder and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Evidence for synergistic modulation of early information processing by nicotinic and muscarinic receptors in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Discovery of an ectopic activation site on the M(1) muscarinic receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

G protein coupling and signaling pathway activation by m1 muscarinic acetylcholine receptor orthosteric and allosteric agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.1.73

21 January 2018

Identifiers

DOI

10.1586/14737175.9.1.73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102670%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference